Have any thoughts about
Seagen Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-61.1
Current
-57.2
Median
4.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-61.1
=
Enterprise Value
38.2B EUR
/
EBITDA
-677.2m USD
All Countries
Close
EBITDA Growth
US
S
Seagen Inc
F:SGT
Average EV/EBITDA: 49.7
Negative Multiple: -61.1
N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
19.5
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.3
53%
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A
AU
CSL Ltd
ASX:CSL
22.5
42%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
230.2
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -93.7 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-53.3
2-Years Forward
EV/EBITDA
-119.9
3-Years Forward
EV/EBITDA
159.7

See Also

Discover More